Search

Displaying results 3751 - 3760 of 10000 in total
  1. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    [A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … [A242005] Ropeginterferon alfa-2b is a next-generation mono-pegylated type I interferon produced from proline-IFN-α-2b in _Escherichia coli_ that has high tolerability and a long half-life.

    Products: BESREMi Pen
  2. Target

    Mitochondrial ATP synthase F1 domain

    go.drugbank.com/bio_entities/BE0010209
    TargetEnzymeHumans

    Part of the complex F(0) domain (PubMed:37244256). … ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256).

    Polypeptides: ATP synthase F(1) complex subunit alpha, mitochondrial, ATP synthase F(1) complex subunit beta, mitochondrial
  3. Drug

    Secretin human

    go.drugbank.com/drugs/DB09532
    ApprovedInvestigational

    The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875]. … Secretin is also responsible in body fluid homeostasis [A32276] and bile production.

    Products: Secretin Iberoinvesa Pharma S.L. 100 CU Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung
  4. Drug

    Mespirenone

    go.drugbank.com/drugs/DB20625
    Experimental

    The usage of the INN stem '-renone' in the name indicates that Mespirenone is a mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonist.

  5. Drug

    Gam-COVID-Vac

    go.drugbank.com/drugs/DB15848
    Investigational

    June 2020, and were completed in early August 2020. … Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia.

  6. Drug

    Treosulfan

    go.drugbank.com/drugs/DB11678
    ApprovedInvestigational

    [L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]

    Products: ALLOPRE 5 G İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADET, ALLOPRE 5 G İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 5 ADET
  7. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. … It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles.

  8. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno". … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.

    Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20
  9. Drug

    INO-4800

    go.drugbank.com/drugs/DB15693
    Investigational

    [A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. … [L14372] A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.[L14375]

    Categories: Complex Mixtures
  10. Drug

    Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15715
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Flulaval Quadrivalent 2020/2021